

Minutes  
December 13, 2004  
Drug Utilization Review (DUR) Board

Members Present: Brendan Joyce, Norm Byers, Bob Treitline, Al Samuelson, Gary Betting, Greg Pfister, Leann Ness, John Savageau, Pat Churchill, Greg Pfister, Carrie Sorrenson, Scott Setzepfandt, Cheryl Huber,

Members absent: Jay Huber

John Savageau (the chair) called the meeting to order at 1:02 pm. The chair asked for a motion to approve the meeting minutes from the 9/27/04 and 11/1/04 meetings. Pat Churchill so moved and Cheryl Huber seconded the motion for the 9/27/04 minutes. Bob Treitline moved to approve the minutes from the 11/1/04 meeting and Greg Pfister seconded this motion. The chair called for two separate voice votes on the two motions, and both passed with no audible dissenters.

The chair asked for an update on the budget. Brendan Joyce reported that for the current fiscal year (through October 2004), the Department is a few hundred thousand dollars to the good, but for the current biennium, the Department is still over budget at the moment and is projecting expenditures to exceed appropriation for pharmacy services by \$3.6 million. Norman Byers asked what is in the Department's budget proposal. Brendan Joyce had no specifics, but reported that the Governor's budget appears to fund the Department to continue to provide services with no cutbacks. The proposed budget includes the savings derived from continued expansion of the prior authorization program.

The chair moved to the next item (ACE Inhibitors). Brendan Joyce presented an algorithm that was derived based on the motion from the previous meeting. He explained that the same grandfathering would be used for these medications, but stabilization on samples would not qualify the patient for exemption from the prior authorization. Much discussion was held regarding the definition of a failure for the medications. Norman Byers suggested that a failure should be side effects or 60 days at an adequate dose without desired response. The chair asked for audience input, and none was volunteered. The chair asked for a motion to approve the algorithm. Greg Pfister moved to accept it and Norm Byers seconded the motion. The chair then asked for a motion to define failure as any side effect or inadequate blood pressure control after 60 days at an adequate dose. Bob Treitline so moved and Norm Byers seconded the motion. The chair asked for a voice vote for the first motion and all approved (no audible dissenters). The chair asked for a voice vote for the second motion and all approved (no audible dissenters). Brendan Joyce then asked the Board to consider a motion to recommend that the Department perform prior authorization on ACE Inhibitors as outlined with the algorithm. Norm Byers so moved and Pat Churchill seconded the motion. The chair asked for a voice vote and it was approved with no audible dissenters.

The chair moved to the next item (ARBs). Brendan Joyce restated the motion as written in the previous meeting's minutes. The chair asked, and no audience members asked to present on the ARBs. Scott Setzepfandt asked if other states had required failure of one class of drugs

before they could start another and if any state required it with ACE's and ARB's. Brendan Joyce responded that he was unsure if any state did this with these two classes of medications, but it has definitely been done time and again with other classes of medications (e.g. H2RA's and PPI's). Norman Byers moved to approve the motion from the previous meeting. Pat Churchill seconded the motion. The chair asked for a voice vote and all approved (no audible dissenters).

The chair moved to the next agenda item (PPI's). Brendan Joyce presented the algorithm for the proposed step therapy for PPI prior authorization. Bob Treitline moved to accept the algorithm. Greg Pfister seconded the motion. Pedro Mendoza presented comments regarding this class of medication. After discussion, the chair called for a voice vote on the motion and it passed with no audible dissenters.

The chair called for a break while John Santa with the Oregon Rx project prepared for his presentation. When the meeting reconvened, John Santa presented his information. Brendan Joyce then presented information regarding the CNS project that is in operation in ND. Copies of these presentations are available upon request.

The chair chose to delay the final agenda item until the next meeting. The next meeting was scheduled for February 14, 2005 at 1 pm. One agenda item will be a 30-minute PhRMA presentation regarding the Oregon Rx project. Scott Setzepfandt shared an article with the DUR Board members. Cheryl Huber moved to adjourn the meeting and Carrie Sorrenson seconded the motion. The chair adjourned the meeting at 3:22 pm.